Virinder Nohria Net Worth

The estimated Net Worth of Virinder Nohria is at least $42.6 million dollars as of 15 June 2016. Virinder Nohria owns over 25,000 units of Horizon Therapeutics Plc stock worth over $22,077,927 and over the last 10 years Virinder sold HZNP stock worth over $20,511,810.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Virinder Nohria HZNP stock SEC Form 4 insiders trading

Virinder has made over 2 trades of the Horizon Therapeutics Plc stock since 2014, according to the Form 4 filled with the SEC. Most recently Virinder sold 25,000 units of HZNP stock worth $442,250 on 15 June 2016.

The largest trade Virinder's ever made was selling 1,739,130 units of Horizon Therapeutics Plc stock on 13 November 2014 worth over $20,069,560. On average, Virinder trades about 252,019 units every 83 days since 2014. As of 15 June 2016 Virinder still owns at least 189,836 units of Horizon Therapeutics Plc stock.

You can see the complete history of Virinder Nohria stock trades at the bottom of the page.

What's Virinder Nohria's mailing address?

Virinder's mailing address filed with the SEC is 1000 HOLCOMB WOODS PARKWAY, SUITE 270, , ROSWELL, GA, 30076.

Insiders trading at Horizon Therapeutics Plc

Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... et Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.

What does Horizon Therapeutics Plc do?

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Complete history of Virinder Nohria stock trades at Horizon Therapeutics Plc

Horizon Therapeutics Plc executives and stock owners

Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:

• Timothy Walbert,
  Chairman of the Board, President, Chief Executive Officer
• Timothy P. Walbert,
  Chairman, Pres & CEO
• Barry Moze,
  Executive Vice President, Chief Administrative Officer
• Paul Hoelscher,
  Chief Financial Officer, Executive Vice President
• Vikram Karnani,
  Executive Vice President, President - International
• Paul W. Hoelscher,
  Exec. VP & CFO
• Andy Pasternak,
  Exec. VP & Chief Strategy Officer
• Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
  Exec. VP & Chief Medical Officer
• Michael Grey,
  Lead Independent Director
• Jeffrey Himawan,
  Independent Director
• H. Thomas Watkins,
  Independent Director
• James Shannon,
  Independent Director
• William Daniel,
  Independent Director
• Pascale Witz,
  Independent Director
• Susan Mahony,
  Independent Director
• Irina Konstantinovsky,
  Chief Human Resource Officer, Executive Vice President
• Daniel Camardo,
  Executive Vice President, President - U.S.
• Jeffrey Kent,
  Senior Vice President, Head of Medical Affairs and Outcomes Research
• Andy Pasternak,
  Executive Vice President, Chief Business Officer
• Geoffrey Curtis,
  Executive Vice President - Corporate Affairs, Chief Communications Officer
• Tina Ventura,
  Senior Vice President, Investor Relations
• Michael DesJardin,
  Executive Vice President - Technical Operations and Corporate Quality
• Brian Beeler,
  Executive Vice President, General Counsel
• Aaron L. Cox,
  Exec. VP of Fin. & CFO
• Jane Gonnerman,
  Group VP of Corp. Devel., Chief of Staff & Office of the CEO
• Geoffrey M. Curtis,
  Exec. VP of Corp. Affairs & Chief Communications Officer
• Sean M. Clayton J.D.,
  Exec. VP & Gen. Counsel
• Timothy Ayers,
  Chief Compliance Officer & VP
• Dr. Karin Rosen M.D., Ph.D.,
  Exec. VP of R&D and Chief Scientific Officer
• Miles W. McHugh,
  Chief Accounting Officer & Sr. VP
• Robert Carey,
  EVP & Chief Business Officer
• Jeff Himawan,
  Director
• Gino Santini,
  Director
• Timothy J. Ackerman,
  SVP, Commercial Operations
• Miles W Mc Hugh,
  Sr VP & Princ. Acctg Officer
• George P Hampton,
  See remarks
• Virinder Nohria,
  Director
• Ronald Pauli,
  Director
• Vaere Robert J De,
  EVP & CFO
• Therapeutics Holdings Llc V...,
  10% owner
• Todd N Smith,
  SVP, Marketing & Alliance Mgmt
• David Happel,
  EVP, Commercial Dev & Strategy
• Eric Mosbrooker,
  SVP, Orphan Business Unit
• Shao Lee Lin,
  EVP, Head of R&D and CSO
• Jeff Kent,
  See remarks
• Jeffrey W Bird,
  Director
• Michael Adatto,
  Senior VP Sales & Managed Care
• Bio Ventures Ii Lp Quaker,
  10% owner
• Venture Fund Vi Lp Atlas Ve...,
  
• Peter Johann,
  Director
• Jean Francois Formela,
  Director
• Venture Fund Vi Lp Atlas Ve...,
  
• Woodlands Health Ventures F...,
  10% owner
• Louis C Bock,
  Director
• Hubert Birner,
  Director
• John B Thomas,
  EVP, Corporate Strategy and IR
• David George Kelly,
  EVP, Company Secretary
• John J Kody,
  EVP, Chief Commercial Officer
• Balaji Venkataraman,
  
• Aaron Cox,
  EVP, Chief Financial Officer
• Jeffrey W Sherman,
  EVP and Chief Medical Officer
• Karin Rosen,
  EVP, R&D & CSO
• Elizabeth H.Z. Thompson,
  EVP, Research & Development
• Sean M. Clayton,
  EVP, General Counsel
• Jacopo Leonardi,
  Pres., Global Commercial Ops
• Patrick Mc Ilvenny,
  Chief Accounting Officer